The 20-gene assay, which BioMérieux will develop on the BioFire FilmArray platform, distinguishes active TB from latent TB, viral, and bacterial infections.
The assay detects a mutation that can confer hearing loss in patients, particularly neonates, who have taken gentamicin, an antibiotic prescribed for certain bacterial infections.
The French firm will assess the ability of its iDtect metagenomic NGS assay to identify pathogenic bacteria and viruses in febrile neutropenia patients.
The startup's technology uses a droplet microfluidics approach for cell isolation and phenotypic detection, and is being targeted for use by hospitals.
PavMed subsidiary Lucid will commercialize Case Western's EsoCheck technology to detect Barrett's esophagus, a precursor to esophageal cancer.
The blood-based test could eventually become a rapid point-of-care diagnostic in the ICU, with startup Microbiome as a commercial vehicle.
The team developed their method to facilitate tumor cell movement through the blood-brain barrier for cancer biomarker detection. The method could eventually lead to the detection of brain cancer using a blood test.
Currently marketed for research use by Biofluidica, the test's microfluidic channels use specific cancer antibodies to detect capture circulating tumor cells.
Using genetic probes and fluorescent scanning, the firm plans to market the $20 test for pathogens that cause urinary tract infections and biological warfare.
The team's portable assay uses digital droplet microfluidics to detect cases of measles and rubella in settings that lack a centralized lab.